Skip to main content

Halstead Michael's Form 4 filing

Intra-Cellular Therapies, Inc. (ITCI) · filed Jan 12, 2024

Accession no.
0000950170-24-004320
Filed
Jan 12, 2024
Trade date
Jan 11, 2024
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $3.34M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Halstead MichaelCIK 0001521548Officer (EVP and General Counsel)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 11, 2024Common StockMOption exerciseAcquired+46,115$12.73+$587,043.9546,115Direct
Jan 11, 2024Common StockMOption exerciseAcquired+3,885$23.94+$93,006.950,000Direct
Jan 11, 2024Common StockSSaleDisposed−18,154$66.31−$1,203,791.7431,846Direct
Jan 11, 2024Common StockSSaleDisposed−30,360$67.10−$2,037,1561,486Direct
Jan 11, 2024Common StockSSaleDisposed−1,486$67.80−$100,750.80Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 11, 2024Common StockMOption exerciseDisposed−46,115$0.00$00Direct
Jan 11, 2024Common StockMOption exerciseDisposed−3,885$0.00$022,869Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)